UroLift vs. Rezum: Revolutionary treatments for BPH relief and long-term health

Written in association with: Mr Matthew Liew
Published: | Updated: 09/12/2024
Edited by: Conor Lynch

Benign prostatic hyperplasia, a common condition among aging men, involves the enlargement of the prostate gland, which can obstruct urine flow and cause bothersome urinary symptoms. Traditional treatments like medications or invasive surgery often come with limitations or significant side effects. However, minimally invasive procedures like UroLift and Rezum have emerged as innovative solutions, offering effective relief with faster recovery times. UroLift is a unique system that alleviates BPH symptoms without cutting or removing prostate tissue.

The procedures

The procedure involves inserting tiny implants to lift and hold the enlarged prostate tissue away from the urethra, allowing for improved urine flow. The treatment is performed under local or light anesthesia, typically in an outpatient setting. UroLift is particularly advantageous for patients seeking symptom relief without compromising sexual function, as it avoids the risks of erectile dysfunction or retrograde ejaculation. Recovery is swift, with most men returning to normal activities within a few days.

 

Rezum, on the other hand, uses the power of water vapor therapy to reduce prostate size. During the procedure, steam is delivered directly into the prostate tissue, causing it to shrink over time as the body absorbs the treated cells. This method is highly effective for moderate to severe BPH and can be performed in a physician’s office under local anesthesia.

 

While Rezum may take several weeks for full symptom improvement, it offers lasting relief without the need for ongoing medication. When comparing the two, UroLift is ideal for men with mild to moderate prostate enlargement and those looking for immediate symptom relief. It’s minimally invasive and preserves sexual function. Rezum is a better fit for men with larger prostates or more severe symptoms, as it effectively reduces prostate size over time. However, the initial recovery period may involve mild discomfort.

 

Both treatments represent a significant advancement in managing BPH, providing men with tailored options to achieve relief and enhance their quality of life. Consulting with a specialist is crucial to determine the most suitable approach based on individual symptoms, prostate size, and overall health goals. Mr Matthew Liew runs a rapid access clinic in Spire Manchester Hospital to fully evaluate men with bothersome enlarged prostates, offering the ‘menu’ of treatment options and completing treatment within weeks of being seen.

By Mr Matthew Liew
Urology

Mr Matthew Liew is a highly accomplished and experienced consultant urologist  specialising in prostate cancerbladder cancerurinary tract infectionskidney stonescircumcision, as well as holmium laser prostate surgery (HoLEP). He is based in Warrington and Manchester, and practises at both the Spire Cheshire Hospital and the Spire Manchester Hospital. He also practises for the NHS at Liverpool University Hospital Foundation Trust.

Mr Liew completed both a MBBS and BMedSci(Hons-first class) degrees at Bart’s and the Royal London Hospital. He has expertise in benign prostate (BPH) surgery, en-bloc bladder tumour resection, transurethral laser ablation (TULA), as well as comprehensive kidney stone management. He is a fully accredited Royal College of Surgeons educational supervisor, as well as a key opinion leader in Endourology. In his NHS practice, he is urology lead for BPH Surgery, Endourology, Teaching, Research and Innovation.

Mr Liew is an incredibly active and renowned researcher, having published over 30 publications on a range of topics, including prostate cancer, kidney stone disease, and education. He is the current Principal Investigator in a number of key international Trials, and Chief Investigator of a bladder cancer trial investigating key risk factors in developing the disease. Impressively, he dedicated time to carry out formal research studying kidney cancer chemotherapy resistance mechanisms at the Christie Hospital, leading to a ‘doctor of medicine’ (MD) award from the University of Manchester in 2013.

He is an associate member of the European Association of Urology Guidelines Panel for Prostate Cancer, Review Editor for Frontiers in Urology Journal and frequently reviews articles for the British Journal of Urology International. He has carried out a number of UK first evaluations, including the use of a novel circumcision procedure. During 2021, Mr Liew was running the only non-cancer urology trial in the UK.

View Profile

Overall assessment of their patients


  • Related procedures
  • Sexually transmitted infections (STIs)
    Vaginoplasty
    Penis Enlargement (Phalloplasty)
    Adult circumcision
    Laparoscopy
    Urologic Oncology
    Geriatric Urology
    Kidney transplantation
    Phimosis
    Short frenulum
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.